Overview

Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C

Status:
Completed

Trial end date:
2010-08-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of MP-424 with Peginterferon Alfa-2b (PEG-IFN) and Ribavirin (RBV) in treatment-naïve patients with (Genotype 1) hepatitis C.

Phase:

Phase 3

Details

Lead Sponsor:

Mitsubishi Tanabe Pharma Corporation

Collaborator:

Vertex Pharmaceuticals Incorporated

Treatments:

Interferon-alpha
Peginterferon alfa-2b
Ribavirin